title: Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
abstract: OBJECTIVE
  Cisplatin is administered in combination with massive hydration to avoid renal toxicity, making its administration difficult in an outpatient setting. Although a short hydration protocol for cisplatin has been recently developed, its safety is not fully understood.
  
  
  METHODS
  Consecutive patients with lung or other cancer and an Eastern Cooperative Oncology Group performance status of 0-2 who were receiving chemotherapy containing cisplatin at a dose of ≥60 mg/m(2) in a single administration were evaluated. Seventy-four patients were treated with a short hydration protocol consisting of 1750-2250 ml of hydration with mannitol and magnesium supplementation over a period of 3.75-4.75 h on Day 1. Sixty-nine patients were treated with a conventional hydration protocol consisting of 2100-2600 ml of hydration over 6.5-7.5 h on Day 1 with pre- and post-hydration on Days 0, 2 and 3. Toxicity was then compared between the two groups.
  
  
  RESULTS
  An elevated serum creatinine level ≥grade 1 was significantly less frequent in the group receiving the short hydration protocol than in the group receiving conventional hydration. Other toxicities were similar between the two groups. Consequently, the completion rate for the planned treatment in the short hydration group (73.0%, 54/74) was significantly higher than that in the conventional hydration group (53.6%, 37/69).
  
  
  CONCLUSIONS
  Short hydration is safe, making cisplatin-containing chemotherapy easier to perform.
authors.affiliation: Department of Hematology, Graduate School of Medicine, Chiba University, Chiba.
authors.forename: Emiko
authors.initials: E
authors.lastname: Sakaida
authors.affiliation: Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba.
authors.forename: Shunichiro
authors.initials: S
authors.lastname: Iwasawa
authors.affiliation: Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba.
authors.forename: Ryota
authors.initials: R
authors.lastname: Kurimoto
authors.affiliation: Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Ebata
authors.affiliation: Division of Pharmacy, Chiba University Hospital, Chiba.
authors.forename: Chiaki
authors.initials: C
authors.lastname: Imai
authors.affiliation: Division of Nursing, Chiba University Hospital, Chiba.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Oku
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba.
authors.forename: Ikuo
authors.initials: I
authors.lastname: Sekine
authors.affiliation: Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Tada
authors.affiliation: Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Tatsumi
authors.affiliation: Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba takiguchi@faculty.chiba-u.jp.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Takiguchi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D004234:Diuretics, Osmotic / Q000008:administration & dosage; D005240:Feasibility Studies; D005260:Female; D005440:Fluid Therapy / Q000379:methods*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008175:Lung Neoplasms / Q000188:drug therapy; D008274:Magnesium / Q000008:administration & dosage; D008297:Male; D008353:Mannitol / Q000008:administration & dosage; D008875:Middle Aged; D010045:Outpatients; D012189:Retrospective Studies; D012449:Safety; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D004234:Diuretics, Osmotic; D008353:Mannitol; D003404:Creatinine; D008274:Magnesium; D002945:Cisplatin
keywords: cisplatin; creatinine; hydration; renal toxicity; short hydration